Testosterone replacement therapy is associated with an increased risk of urolithiasis

World Journal of Urology Nov 28, 2019

McClintock TR, Valovska MTI, Kwon NK, et al. - In this population-based matched cohort study using data sourced from the Military Health System Data Repository of men aged 40–64 years with no former history of urolithiasis who received continuous testosterone replacement therapy (TRT, n = 26,586) for a diagnosis of hypogonadism between 2006 and 2014, experts ascertained whether TRT in men with hypogonadism was related to a progressed risk of urolithiasis. Among those on TRT, in comparison with those who did not undergo this hormonal therapy, an improvement in the 2-year absolute risk of stone events was noted.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay